GSK’s antibody-drug conjugate Blenrep has secured regulatory approvals as a second-line treatment in Europe and Canada, signaling a comeback for the drug in multiple myeloma therapies. Despite these approvals, dose optimization concerns have stalled its U.S. regulatory progress, leaving the American market pending. The approvals abroad provide a regulatory foothold for GSK while unresolved questions delay domestic commercialization.